Pegcetacoplan

Summary

Pegcetacoplan is a pegylated cyclic peptide that inhibits complement component C3. It is approved for treating paroxysmal nocturnal hemoglobinuria (PNH) and is being investigated for dry age‑related macular degeneration (geographic atrophy) and complement‑mediated kidney disorders such as C3 glomerulopathy and immune‑complex membranoproliferative glomerulonephritis.

Mechanism of Action

Pegcetacoplan binds to the central complement protein C3 and its activation fragment C3b, preventing cleavage to C3a and C3b and blocking downstream formation of the C5 convertase. By acting upstream of C5, it reduces both intravascular hemolysis (via membrane‑attack complex formation) and extravascular hemolysis (via C3b opsonisation). The pegylated structure prolongs systemic exposure, allowing subcutaneous dosing, while intravitreal delivery targets local complement activation in the retina.

What the Research Shows

Phase 3 trials in PNH demonstrated that subcutaneous pegcetacoplan raised hemoglobin by ~3.8 g/dL, reduced transfusion dependence (85% vs 15% with eculizumab), and lowered LDH compared with both eculizumab and supportive care. In the VALIANT kidney trial, pegcetacoplan reduced proteinuria by 67% versus placebo and increased the proportion achieving renal composite endpoints, without excess adverse events. A review of dry AMD notes phase 3 evidence that intravitreal pegcetacoplan slows geographic atrophy growth. Reviews of IgA nephropathy highlight ongoing studies of pegcetacoplan among other complement inhibitors. Safety data across studies show a tolerable profile but note injection‑site reactions and mild gastrointestinal symptoms.

Reported Benefits

In PNH, pegcetacoplan improves anemia, lessens transfusion needs, and curtails hemolysis markers, translating into better fatigue scores. In complement‑mediated kidney disease, it markedly lowers proteinuria and supports renal function stabilization. Intravitreal administration in dry AMD appears to decelerate geographic atrophy expansion, offering a disease‑modifying option where few therapies exist. Across indications, the drug provides broader complement blockade than C5‑targeted agents.

Limitations of the Evidence

Evidence is currently limited to clinical trials; pegcetacoplan is approved only for PNH, not for AMD or kidney diseases. In the kidney trial, histologic activity scores did not improve, and long‑term renal outcomes remain uncertain. Data on visual outcomes in AMD are limited to phase 3 results without real‑world confirmation. The safety profile, while acceptable, includes frequent injection‑site reactions and mild GI effects, and rare serious infections have not been observed but cannot be excluded. Cost and access considerations are not addressed in the literature.

Safety Considerations

Common adverse events are injection‑site reactions (≈37% in PNH studies) and diarrhea (≈22%). Headache, fatigue, and occasional breakthrough hemolysis have been reported. No meningitis or serious encapsulated bacterial infections occurred in the PNH trials; one death from COVID‑19 pneumonia was noted in the kidney study. Overall, pegcetacoplan was well tolerated, with no new safety signals in the reported trials, but monitoring for infections and infusion‑related reactions is advised.

How It Is Administered

Pegcetacoplan is administered subcutaneously twice weekly for systemic indications such as PNH and complement‑mediated kidney disease. For ophthalmic use, it is delivered by intravitreal injection to target retinal complement activation in geographic atrophy. Formulations are pegylated peptide solutions suitable for these routes.

Routes of Administration

Goals & Uses

• Treatment of complement-mediated hemolytic anemiasHematologyModerate
• Reduction of extravascular hemolysis in PNHHematologyHigh
• Treatment of paroxysmal nocturnal hemoglobinuria (PNH)Hematology / Rare DiseaseHigh
• Treatment of geographic atrophy (GA) in AMDOphthalmologyHigh
• Paroxysmal nocturnal hemoglobinuriaHematologyHigh

Contraindications

• Unresolved Neisseria meningitidis infectionInfectious DiseaseHigh
• Hypersensitivity to pegcetacoplan or excipientsAllergy/ImmunologyHigh
• Hypersensitivity to pegcetacoplan or PEGHypersensitivityModerate
• Unvaccinated patients (encapsulated organisms)Infectious DiseaseHigh

Adverse Effects

• Infusion-related reactions (intravitreal: conjunctival hemorrhage, floaters)OphthalmologicCommon
• Serious infections (encapsulated bacteria)Infectious DiseaseUncommon
• Injection site reactionsLocalCommon
• HeadacheNeurologicCommonPain in the head or upper neck
• Hemolysis upon discontinuationHematologicUncommon
• FatigueGeneralCommonLow energy or tiredness
• InfectionsImmunologicCommon
• Diarrhea / gastrointestinal symptomsGastrointestinalCommon
• DiarrheaGastrointestinalUncommonLoose or frequent stools

Drug Interactions

• Live attenuated vaccinesModerate
• Vaccines (live attenuated)Moderate
• Eculizumab / RavulizumabModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Severe renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Patients with active systemic infectionsInfectious DiseaseRelative
• BreastfeedingReproductiveRelative

Regulatory Status

• European UnionApprovedApproved: Paroxysmal nocturnal hemoglobinuriaApproved in 2022.
• United StatesApprovedApproved: Paroxysmal nocturnal hemoglobinuriaApproved in May 2021 (Empaveli).
• United KingdomApprovedApproved: Paroxysmal nocturnal hemoglobinuria (PNH) in adultsMHRA approved following EMA decision; NICE technology appraisal conducted.

First FDA‑approved C3 inhibitor (Empaveli).

Evidence & Sources

• Treatment of dry age-related macular degeneration: A review
  Journal ArticleModerateGirgis S, Lee LR2023-01-01T00:00:00.000000Z
• Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
  Journal ArticleModerateHillmen P, et al.2021-01-01T00:00:00.000000Z
• Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
  Journal ArticleModerateFakhouri F, et al.2025-01-01T00:00:00.000000Z
• Targeting complement in IgA nephropathy
  Journal ArticleModerateCaravaca-Fontán F, et al.2023-01-01T00:00:00.000000Z
• Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy
  Journal ArticleModerateBarcellini W, Fattizzo B2024-01-01T00:00:00.000000Z
• Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria
  Journal ArticleModerateWong RSM, et al.2023-01-01T00:00:00.000000Z

Frequently Asked Questions